EOS imaging Will Present Its EOS Solution for Patient-Specific Treatment at the Francophone Radiology Days (JFR) Congress in Paris

Published: Oct 11, 2018

 
PARIS--(BUSINESS WIRE)-- Regulatory News:

EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - SME), a pioneer in 2D / 3D orthopedic medical imaging, will present its 2D / 3D collaborative data sharing solution, stereoVIEW, as well as its new online learning platform at the Francophone Radiology Days (JFR) Congress, which will take place October 12-15, at the Palais des Congrès in Paris.

The event allows imaging professionals to discuss the latest technological and scientific advances in medical imaging and brings together clinical as well as basic and industry research. This year’s theme will focus on appropriate imaging for targeted and personalized treatment.

During JFR, EOS® solution will be highlighted in several scientific sessions and posters on osteoarticular imaging of the lower limbs and spine. In particular, a presentation by Dr. Laurence Mainard-Simard from Nancy will highlight first results from a study using a sterEOS prototype with artificial intelligence, including deep learning algorithms, for the automatic modeling of a 3D spine in standing position. The session will be held on Saturday, October 13 at 4:21pm CET in Room 253.

Furthermore, EOS imaging will specifically highlight its stereoVIEW application for collaborative sharing of 2D and 3D data between radiologists, physicians, and patients. StereoVIEW allows 3D models and clinical parameters to be visualized to share diagnostic and treatment options with patients and facilitate exchange with referring physicians.

EOS teams will also present its new certified online training platform. This innovative tool allows physicians and other healthcare professionals to train on EOS low dose imaging solution, sterEOS 2D / 3D modeling and analysis, as well as the EOSapps 3D surgical planning software suite. Training is provided as classical courses and / or certifications.

"We are pleased to present new and innovative tools to further enhance the value of the EOS suite in the treatment of osteoarticular pathologies at JFR. We continue to focus on improving imaging care and facilitating the work of radiologists as we support the growing adoption of our solutions," concluded Marie Meynadier, Chief Executive Officer of EOS imaging.

For more information, visit us at EOS Booth #113, Hall Passy, Level 1 or feel free to email us at: contact@eos-imaging.com

ABOUT EOS IMAGING

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 33 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 280 installed EOS® platforms representing more than one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017. For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA - PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

 

Contacts

EOS imaging
Marie Meynadier
CEO
Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com
or
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com
or
Press Relations (US)
Kirsten Thomas
The Ruth Group Ph: 508-280-6592
kthomas@theruthgroup.com

 
 

Source: EOS imaging

Back to news